Neuromelanin-Sensitive MRI Linked to Psychosis Severity in Schizophrenia
By Elana Gotkine HealthDay Reporter
MONDAY, Nov. 20, 2023 -- Neuromelanin-sensitive magnetic resonance imaging (NM-MRI) contrast is associated with psychosis severity in antipsychotic-free patients with schizophrenia, according to a study published online Nov. 8 in JAMA Psychiatry.
Kenneth Wengler, Ph.D., from Columbia University in New York City, and colleagues conducted a cross-sectional study involving 42 antipsychotic-free patients with schizophrenia, 53 antipsychotic-free individuals at clinical high risk for psychosis (CHR), and 52 matched healthy controls to replicate previous findings relating NM-MRI, a proxy measure of dopamine function, to psychosis severity. Data were also included for an external validation sample of 16 antipsychotic-naive patients with schizophrenia.
The researchers found that higher Positive and Negative Syndrome Scale positive total scores correlated with higher mean NM-MRI contrast in the psychosis regions of interest (ROI) in the schizophrenia sample. No significant association was found between a higher Structured Interview for Psychosis-Risk Syndromes positive total score and NM-MRI contrast in the psychosis ROI in the CHR sample. In held-out test data, the 10-fold cross-validated prediction accuracy of psychosis severity was above chance; prediction accuracy of external validation was also above chance.
"We provided a direct replication of the in-sample association between NM-MRI contrast and psychosis severity in antipsychotic-free schizophrenia. In turn, we failed to replicate such an association with CHR," the authors write.
Wengler disclosed having filed patents for the analysis and use of NM-MRI in central nervous system disorders.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.